Article

Skeletal development research may identify new osteoarthritis therapies

A multidisciplinary team at the UC Davis Health System is conducting experiments to confirm the relationship between osteoarthritis (OA) and Maf factors

A multidisciplinary team at the UC Davis Health System is conducting experiments to confirm the relationship between osteoarthritis (OA) and Maf factors-a family of cell regulators important to the formation and growth of healthy bones and cartilage-by identifying genetic targets in cartilage that they control. Maf factors may play an important role in cartilage breakdown in early bone development and as persons age, and learning about the genetic regulators that are active during the breakdown process can improve understanding of how to treat patients with OA before surgery is necessary, according to researchers in the UC Davis Health System department of orthopedic surgery. Their comprehensive approach to understanding the cellular processes that prevent OA can lead to nonsurgical therapies that can stop or slow the disease process or enhance cartilage growth, the investigators stated.

For more information about the UC Davis Health System department of orthopedic surgery, visit the department's Web site at http://www.ucdmc.ucdavis.edu/orthopaedics. Or, contact the organization at UC Davis Health System, 4900 Broadway, Suite 1200, Sacramento, CA 95820; telephone: (916) 734-9040; fax: (916) 734-9066.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.